Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool November 4, 2005 Rich Duprey	Merck Eases Its Pain The pharmaceutical giant wins an important Vioxx trial. And while it's a welcome reprieve for the company, the decision doesn't seem to warrant the enthusiasm with which the market greeted the decision.
The Motley Fool April 3, 2006 Rich Duprey	Merck Outclassed Class action status is granted to third parties -- like health insurance companies, HMOs, and unions -- in a Vioxx lawsuit. Investors, this is a disturbing development.
The Motley Fool December 13, 2005 Rich Duprey	Merck's Bitter Pill The first federal Vioxx trial ends with a deadlocked jury, but that's not necessarily good news for the drugmaker, or investors.
The Motley Fool August 22, 2005 Stephen D. Simpson	Vioxx Brings the Pain A jury stings Merck for hefty Vioxx damages, battering shares.
The Motley Fool August 2, 2007 Brian Orelli	98 Lawsuits Down, About 15,000 To Go Merck's Vioxx caseload just got a little smaller, when an appellate court ruled that 98 people from England and Wales could not sue in the U.S. Shares are up on the news.
BusinessWeek July 30, 2007	Another Risk Factor For Merck Plaintiffs' lawyers are salivating over evidence they hope could support their argument that even patients who used the painkiller for short periods were in danger.
Chemistry World March 13, 2007	Vioxx Trial Blow for Merck A jury has awarded $47.5 million to an Idaho man after finding that the anti-inflammatory drug Vioxx, made by Merck and Co., Inc., contributed to his heart attack.
The Motley Fool March 1, 2006 Rich Duprey	Celebrex Doubles Lawsuit Risk A new study says the Pfizer painkiller doubles the risk of a heart attack. Investors, beware.
The Motley Fool May 30, 2008 Brian Orelli	For Merck, Hindsight Hurts Even after dragging its feet for years, one has to wonder if Merck settled the Vioxx cases a little too quickly?
BusinessWeek September 5, 2005 Amy Barrett	The Pain Is Just Beginning Why the Vioxx debacle will hobble Merck for years to come
The Motley Fool September 7, 2007 Billy Fisher	Epic Vioxx Victory for Merck Merck scores a major victory in its Vioxx saga in the courtroom as New Jersey's Supreme Court rules against the possibility of a national class action Vioxx lawsuit. Shares react positively.
The Motley Fool January 25, 2005 Stephen D. Simpson	Prognosis Good for Merck The pharmaceutical weathered a tough year but should ride out its Vioxx troubles. While strict value investors may be put off, risk-tolerant investors can buy these shares today.
The Motley Fool September 11, 2008 Brian Orelli	Vive le Vioxx Lawsuit Just when Merck thought it was finally done with lawsuits pertaining to Vioxx, it's gotten pulled back in.
BusinessWeek December 5, 2005 Michael Orey	Presto: A New Vioxx Liability Estimate! Why analysts' reports shift wildly with every twist in litigation against Merck.
The Motley Fool October 23, 2006 Brian Lawler	Merck Mints Money The pharmaceutical hangs on, despite ongoing Vioxx woes. Conservative investors may do best to stay away from Merck until a lower share-price opportunity presents itself, now that shares are no longer sporting such a large Vioxx discount.
The Motley Fool August 26, 2005 Stephen D. Simpson	Merck Broaches the Obvious Merck will naturally end up settling many Vioxx cases, but the details are far from clear at this point. Investors, take note.
The Motley Fool January 31, 2007 Brian Lawler	Merck Plays the Waiting Game New acquisitions may help the drugmaker weather tough times. Investors, take note.
The Motley Fool November 15, 2004 Mathew Emmert	Merck's Silver Lining The government joins the plethora of lawsuit filers, but Merck will survive. Still, the stock remains appropriate for only those investors with a high tolerance for risk and a long-term time horizon.
The Motley Fool September 18, 2007 Brian Orelli	New York Tag-Teams Merck Both the city and state of New York sue Merck over Vioxx payments, alleging the big pharma defrauded Medicaid and other government agencies, by hiding problems related to its painkilling drug.
The Motley Fool July 23, 2007 Brian Lawler	Merck Not Hurt Merck repeats another nice quarter of bottom-line growth despite growing concerns about generic competition.
The Motley Fool October 21, 2004 Brian Gorman	Merck Is Down But Not Out The pharma's woes may have silver linings. For now, the company's investors might want to sit tight.
The Motley Fool March 7, 2008 Brian Orelli	A Heavy Price for Wyeth and Pfizer They're ordered to pay millions because their hormone therapies may carry a higher risk of breast cancer.
The Motley Fool December 21, 2006 Brian Lawler	Dueling Fools: Merck Bull What you are getting with Merck is one of the best-managed pharmas out there that will be experiencing solid double-digit earnings growth in the not-too-distant future with a smart dividend payout.
The Motley Fool February 23, 2005 Stephen D. Simpson	Take Two on COX-2 FDA panel recommendations breathe new life into Merck and Pfizer's COX-2 pain medications. Looking ahead, investors should give a good, long look to the drug sector.
The Motley Fool April 17, 2007 Brian Lawler	Merck Raises the Earnings Roof Shares of Merck soar after it raises 2007 earnings guidance.
BusinessWeek April 21, 2011 Tom Randall	Merck's Risky Bet on Research CEO Frazier, who made his name fighting drug lawsuits, is investing billions to churn out new medicines.
The Motley Fool February 21, 2006 Rick Aristotle Munarriz	Biggest Disappointment: Merck In the spirit of the Winter Olympics, here are stock challenges from the publication's writers: Merck is rich in cash, tradition, and potholes.
The Motley Fool May 21, 2008 Brian Orelli	OK, Last Vioxx Settlement, Honest! What's another $58 million when Merck's already forking over $4.85 billion?
BusinessWeek May 20, 2010 Bob Van Voris	Big Tobacco's Many Days in Court Facing thousands of lawsuits in Florida, cigarette makers are crying foul.
The Motley Fool January 26, 2006 Rich Duprey	Will Acquisitions Patch Merck's Pipeline? The pharmaceutical giant announces a biotech shopping spree. A few key acquisitions that contribute late-stage drugs and significant revenue might be all Merck needs to keep its pipeline open. Investors, take note.
The Motley Fool December 8, 2004 Alyce Lomax	Eli Lilly Bares All The pharmaceutical publishes clinical trial results online. This is a step toward generating trust -- after all, shareholders, physicians, and consumers alike are likely looking askew at Big Pharma these days.
The Motley Fool November 13, 2007 Brian Orelli	Merck: Case Closed? Now that Merck has settled its lawsuit, it can get back to business, focusing on continued growth from its cholesterol drugs, new diabetic medication, and cervical cancer vaccine. Investors, take note.
The Motley Fool November 8, 2004 Brian Gorman	Pfizer's Gloom Factor The stock will continue to be depressed, but things will improve if Celebrex's safety is proven.
Bio-IT World December 15, 2004 Kevin Davies	Patients Before Profits? After the Vioxx disaster, Pharma needs to reassure patients that they come first.
BusinessWeek December 13, 2004 Amy Barrett	On The Firing Line At Embattled Merck With claims against Vioxx mounting, Merck's general counsel Ken Frazier is in for the fight of his career.
The Motley Fool October 24, 2005 Stephen D. Simpson	Merck Needs to Take Its Medicine It will be a long, long time before business at the pharmaceutical returns to business as usual. Turnarounds can pay off for patient investors.
The Motley Fool October 4, 2004 Mathew Emmert	Got Merck? The pharmaceutical's investors can't seem to catch a break.
The Motley Fool September 30, 2004 W. D. Crotty	Merck Chokes Back Vioxx The $2.3 billion arthritis drug is withdrawn from the market after clinical studies point to dangerous side-effects. Despite the bad news, Merck's big dividend payouts don't appear to be in jeopardy at the moment.
The Motley Fool June 23, 2005 Rich Smith	Dueling Fools: Merck Bull It's hard to argue with a price this cheap. With a price-to-free cash flow ratio of less than 11, Merck's a steal.
The Motley Fool June 23, 2005 Stephen D. Simpson	Dueling Fools: Merck Bear Looking at other big pharma peers, Merck is dead last when it comes to expected three- to five-year EPS growth. Why buy a troubled pharma when better options exist?
The Motley Fool October 23, 2007 Brian Orelli	Old Merck on New Drugs It looks like the old Merck is back, with new drugs driving double-digit sales growth in the third-quarter.
The Motley Fool June 3, 2005 Brian Gorman	Merck's New Innovation Pending FDA approval, the company's experimental shingles vaccine will probably be a steady earner. In the near term, the stock isn't going to see huge gains, but the company is here to stay and will keep innovating.
The Motley Fool February 8, 2008 Brian Orelli	Merck in Lukewarm Water The pharmaceutical's settlement ends a government probe into Medicaid overcharging allegations.
InternetNews February 19, 2009 Stuart J. Johnston	Judge Decertifies Class in 'Vista Capable' Suit Instead of millions of plaintiffs, Microsoft only has to fight six, but it's not out of the woods just yet.
The Motley Fool November 25, 2009 Brian Orelli	Still Enjoying Those Acquisitions, Pfizer? The drug company has inherited a lot in its acquisitions of Warner-Lambert, Pharmacia, and Wyeth. And of course, those 10,000 lawsuits.
Pharmaceutical Executive January 1, 2013	Product Liability Claims and Comment K Courts across the country are making it easier to prove that a drug is unsafe, warning label notwithstanding.
The Motley Fool December 21, 2004 Brian Gorman	Pfizer Won't Let Go Pfizer is hoping that Celebrex will survive in some form. But the pharmaceutical giant has also determined that the drug should no longer be advertised to consumers. Its shares were pounded again following its revelation that it would pull such ads.
BusinessWeek July 25, 2005 Gene G. Marcial	Is Merck Rallying After That Nasty Tumble? Although most analysts who track Merck remain bearish on the beleaguered drugmaker, some upbeat investors are buying. Why? It's Vioxx market may have softened, but its new vaccines will rise to the occasion.
BusinessWeek July 30, 2007 Arlene Weintraub	Is Merck's Medicine Working? Spurred by the Vioxx fiasco, CEO Clark is trying to revamp the drug giant's culture. Analysts expect Merck's top line to grow 4%, to $23.5 billion this year, an achievement considering that sales growth had flatlined even before Vioxx imploded.
The Motley Fool June 23, 2005 Rich Smith	Dueling Fools: Merck Bull Rebuttal Priced at a P/E of 13 and paying you a 4.8% dividend, Merck isn't just affordable -- it's a stock you can't afford not to own.